|Over a week ago|
B. Riley starts F-star Therapeutics at Buy, sees 307% potential upside » 07:3706/0906/09/21
B. Riley analyst Justin…
B. Riley analyst Justin Walsh last night initiated coverage of F-star Therapeutics with a Buy rating and $28 price target, which represents 307% potential upside from current levels. F-star is a clinical-stage immuno-oncology biotech company whose bispecific antibody platform has moved three assets into the clinic targeting unmet needs in the multi-billion-dollar solid tumor checkpoint inhibitor market, Walsh tells investors in a research note. The analyst sees the "steady cadence of data readouts" expected across F-star's clinical assets as providing the "potential fuel needed to further de-risk its platform and pipeline."
F-star Therapeutics initiated with a Buy at B. Riley » 19:1606/0806/08/21
B. Riley initiated…
B. Riley initiated coverage of F-star Therapeutics with a Buy rating and $28 price target.
Inivata, F-star Therapeutics collaborate for use of RaDaR assay » 07:0605/2505/25/21
Inivata announced a…
Inivata announced a collaboration with F-star Therapeutics for the use of Inivata's RaDaR technology. Under the collaboration, Inivata's RaDaR technology, a personalized assay that tracks a set of up to 48 tumor-specific variants in a patient using a liquid biopsy with exceptional sensitivity, will be applied to identify and evaluate potential early biomarkers of clinical efficacy.
F-star Therapeutics takes 5.7% passive stake in F-star Therapeutics » 16:4105/1805/18/21
Point72 Asset Management…
Point72 Asset Management disclosed a 5.7% stake in F-star Therapeutics, which represents 1.1M shares. The filing does not allow for activism.
|Over a month ago|
F-star Therapeutics expects cash to fund operating plans into 2H23 » 08:1505/1705/17/21
Cash and cash equivalents…
Cash and cash equivalents as of March 31, 2021 were $3.7 million, compared to $18.5 million at December 31, 2020. Based on the Company's current operating plan, the Company believes its cash and cash equivalents at March 31, 2021, together with the net proceeds from the recent sales of common stock in the underwritten public offering and under the ATM, and funds from its debt facility will be sufficient to fund its current operating plans into the second half of 2023.
F-star Therapeutics reports Q1 EPS ($1.08), consensus ($1.16) » 08:1405/1705/17/21
Reports Q1 revenue $2.9M,…
Reports Q1 revenue $2.9M, consensus $1.2M. Eliot Forster, CEO of F-star Therapeutics, Inc., said, "I'm very proud of what F-star accomplished in our first full quarter as a publicly traded company. The successful close of our public offering means we have now strengthened our financial position to ensure delivery on our future milestones. We have made excellent progress across all four clinical stage programs. We have also delivered with our partners, as noted in the recent update on our collaboration with Merck KGaA. We have added new insights into the unique properties of our platform technology, including presenting new data on FS222, our potentially best-in-class bispecific antibody targeting CD137 and PD-L1. This year will be another exciting one for F-star with clinical data expected and huge potential to provide transformational treatment options for patients with cancer."
F-star Therapeutics 9.286M share Secondary priced at $7.00 » 08:0205/0705/07/21
SVB Leerink acted as lead…
SVB Leerink acted as lead book running manager for the offering.
F-star Therapeutics announces common stock offering, no amount given » 16:5305/0605/06/21
F-star Therapeutics announced that it has commenced an underwritten public offering of its common stock. F-star intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, for working capital and general corporate purposes, including, but not limited to, clinical trials, research and development activities and capital expenditures. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. SVB Leerink is acting as sole bookrunning manager for the offering.
new option listings and three option delistings on April 21st » 08:3004/2104/21/21
APP, BSPE, CFB, CHRA, CTEC, CYCC, DFNS, FARM, FSTX, GENI, GNPK, IDEV, INFU, JOAN, MAX, NVVE, OBLG, PSI, SCPH, SMIN, SNSR, WKEY, XFOR, ZKIN, CBPO, DMYD, IPHI
New option listings for…
New option listings for April 21st include First Trust RBA American Industrial Renaissance (AIRR), Applovin Corporation (Class A Stock) (APP), Bespoke Capital Acquisition Corporation (Class A Stock) (BSPE), CrossFirst Bankshares Inc (CFB), Charah Solutions Inc (CHRA), Global X CleanTech ETF (CTEC), Cyclacel Pharmaceuticals (CYCC), LGL Systems Acquisition Corp (Class A Stock) (DFNS), iShares Emerging Markets Dividend (DVYE), iShares MSCI Emerging Markets Asia (EEMA), Farmer Bros. (FARM), F star Therapeutics Inc (FSTX), First Trust Nasdaq Oil and Gas (FTXN), First Trust Nasdaq Bank (FTXO), First Trust Nasdaq Transportation (FTXR), First Trust Small Cap Core AlphaDEX Fund (FYX), Genius Sports Limited (GENI), Genesis Park Acquisition Corp (Class A Stock) (GNPK), iShares Core MSCI International Developed Markets ETF (IDEV), InfuSystem (INFU), iShares Russell Top 200 Growth (IWY), iShares US Consumer Services (IYC), iShares US Consumer Goods (IYK), JOANN Inc (JOAN), MediaAlpha Inc (Class A Stock) (MAX), Nuvve Holding Corporation (NVVE), Oblong Inc (OBLG), PowerShares Dynamic Semiconductors Portfolio (PSI), scPharmaceuticals Inc (SCPH), iShares MSCI India Small Cap ETF (SMIN), Global X Internet of Things Thematic (SNSR), Soaring Eagle Acquisition Corporation (Units) (SRNGU), iShares Core US REIT ETF (USRT), Vanguard International Dividend Appreciation ETN (VIGI), WISeKey International Holdings SA (ADR) (WKEY), X4 Pharmaceuticals Inc (XFOR), and ZK International Group Co Ltd (ZKIN). Option delistings effective April 21st include China Bioligic Products Holdings Inc (CBPO), dMY Technology Group Inc II (Class A Stock) (DMYD), and Inphi Corporation (IPHI).
F-star Therapeutics announces publication of study on SB 11285 » 09:3004/1904/19/21
F-star Therapeutics announced the publication of a new study, conducted by Yale University and F-star, of its second generation STING agonist, SB 11285, in the current issue of Nature Communications. The study entitled "STING enhances cell death through regulation of reactive oxygen species and DNA damage" demonstrates that systemic administration of a STING agonist in combination with radiation in a preclinical model enhances local control in Head and Neck Squamous Cell Carcinoma and suggests that STING expression in the tumor is required for maximal therapeutic benefit. Resistance to DNA-damaging agents such as radiation is a significant cause of treatment failure and poor outcomes in oncology. To identify unrecognized regulators of cell survival, the researchers performed a whole-genome CRISPR-Cas9 screen following treatment with ionizing radiation and identified STING as an intrinsic regulator of tumor cell survival. In addition, the study showed that STING overexpression restored tumor cell sensitivity to ionizing radiation and that STING loss confers resistance to DNA damaging therapies. Analysis of tumors from HNSCC patient specimens showed that low STING expression is associated with poor outcomes. The research also demonstrated that pharmacologic activation of STING enhances the effects of ionizing radiation in vivo, providing a rationale for therapeutic combinations of STING agonists and DNA-damaging agents as well as a strong rationale for investigating STING expression as a predictive biomarker.